Cleared Traditional

DSP100 CAROTID PHONOANGIOGRAPHY MODULE (K864429) - FDA 510(k) Clearance

Class I Cardiovascular device.

K864429 · Intl. Acoustics, Inc. · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
May 1987
Decision
181d
Days
Class 1
Risk

K864429 is an FDA 510(k) clearance for the DSP100 CAROTID PHONOANGIOGRAPHY MODULE. Classified as Phonocardiograph (product code DQC), Class I - General Controls.

Submitted by Intl. Acoustics, Inc. (Palatine, US). The FDA issued a Cleared decision on May 12, 1987 after a review of 181 days - an extended review cycle.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.2390 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Cardiovascular review framework, consistent with the majority of Class II 510(k) submissions.

View all Intl. Acoustics, Inc. devices

Submission Details

510(k) Number K864429 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 12, 1986
Decision Date May 12, 1987
Days to Decision 181 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
56d slower than avg
Panel avg: 125d · This submission: 181d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code DQC Phonocardiograph
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 870.2390
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.